DUBLIN – Motif Bio plc is on course for an NDA filing next year for its diaminopyrimidine antibiotic, iclaprim, following a positive readout from the first of two phase III trials in patients with acute bacterial skin and skin structure infection (ABSSSI), in which it demonstrated noninferiority to vancomycin. Results from a second study, which is following the same protocol, are due in the second half of this year.